A phase II trial of LBH589 in refractory myelodysplastic syndromes (MDS) patients

Trial Profile

A phase II trial of LBH589 in refractory myelodysplastic syndromes (MDS) patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Panobinostat (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Nov 2015 Status changed from completed to discontinued as reported by
    • 03 May 2011 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 May 2011 Planned end date changed from 1 Jan 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top